YAG2 Stock Overview
A clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Atossa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$1.84 |
| 52 Week Low | US$0.73 |
| Beta | 1.19 |
| 11 Month Change | -3.49% |
| 3 Month Change | -27.50% |
| 1 Year Change | -0.082% |
| 33 Year Change | -73.02% |
| 5 Year Change | n/a |
| Change since IPO | -47.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| YAG2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 0.8% |
| 1Y | -0.08% | -18.9% | 2.0% |
Return vs Industry: YAG2 exceeded the German Biotechs industry which returned -18.9% over the past year.
Return vs Market: YAG2 underperformed the German Market which returned 2% over the past year.
Price Volatility
| YAG2 volatility | |
|---|---|
| YAG2 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: YAG2's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine YAG2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Steve Quay | www.atossatherapeutics.com |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs.
Atossa Therapeutics, Inc. Fundamentals Summary
| YAG2 fundamental statistics | |
|---|---|
| Market cap | €139.70m |
| Earnings (TTM) | -€27.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs YAG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YAG2 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.69m |
| Earnings | -US$29.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did YAG2 perform over the long term?
See historical performance and comparison